<DOC>
	<DOCNO>NCT01883011</DOCNO>
	<brief_summary>The aim study confirm efficacy piracetam 12 week treatment aphasic status subject suffer aphasia acute ischemic middle cerebral artery stroke receive medication within 7 h post-stroke onset .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Piracetam Aphasia After Acute Ischemic Cerebral Artery Stroke</brief_title>
	<detailed_description>An interim analysis perform , plan protocol , primary efficacy measure ( Day 84 FAST Score ) aphasic subject . This interim analysis indicate less 20 % chance show 15 % difference placebo piracetam end trial , assumption indeed 15 % difference . Thus , decision UCB stop recruitment study .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<criteria>Male female adult ≥ 50 year Considered reliable mentally capable adhere protocol Signed informed consent ( subject next kin ) inclusion subject per Ethics Committee approve procedure Clinical diagnosis middle cerebral artery ischemic stroke A disable motor deficit moment inclusion , define total Middle Cerebral Artery ( MCA ) score 15 65 Treated 7 h ( 6 h 59 minute ) estimate stroke onset If subject stroke night , onset stroke assume last time subject see awake normal , last time subject remember he/she awake normal Being aphasic , defined Aphasia Severity Rating ( ASR ) score &lt; 3 Stupor coma : &lt; 10 item consciousness Middle Cerebral Artery ( MCA ) scale A previous stroke clinical sequel previous stroke aphasia ( even case complete recovery aphasia ) A medical neurological disease interfere assessment cause clear deficit : 1. functional ability autonomy 2. motor function 3. cognitive capacity 4. language A systemic disease neurological symptom A life threaten disease life expectancy le 1 year Renal insufficiency ( creatinine &gt; 2 mg/100 ml &gt; 180 µmol/l ; creatinine determine soon possible inclusion ) Any concomitant treatment could stop moment inclusion start onset stroke inclusion ( long consider advisory board effective drug ) , : 1 . Cerebrovascular active product : bufenine , buflomedil , cinnarizine , codergocrinemesilate , citicholine , cyclandelate , cyprodemanol , deanolacetamidobenzoate , flunarizine , ginkgobiloba extr. , inositolnicotinate , isoxsuprine , meclofenoxate , naftidrofuryloxalate , nicergoline , nicotinic acid ( smoke allow ) , nimodipine , pentifylline , papaverine , pentoxifylline , piracetam , pyrisuccideanoldimaleate , pyritinol , raubasine , vincamine , viquidil , xantinolnicotinate . A list drug generic brand name , adapt participate country accompany Case Report Form ( CRF ) 2 . Thrombolytics : recombinant tissuetype plasminogen activator ( alteplase ) ( rt PA ) , streptokinase , urokinase , ancrod 3 . Hemodilution 4 . Glucose infusion &gt; 5 % Subjects know able follow 12 week Known alcohol drug addiction abuse Subjects previously enrol trial Known allergy/intolerance piracetam/excipients Lactation , pregnancy , pregnancy potential , unless use effective mean contraception Illiterate subject ( subject able read prior stroke )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Piracetam</keyword>
	<keyword>Stroke</keyword>
	<keyword>Aphasia</keyword>
	<keyword>Acute</keyword>
	<keyword>Cerebral</keyword>
	<keyword>Ischemic</keyword>
	<keyword>Nootropil</keyword>
</DOC>